Moreover, it seems that Sitagliptin has proven efficacy against acute respiratory distress syndrome (ARDS), the common causes of COVID-19-related death, because this drug inhibits IL-6, IL-1, and TNF in individuals with lung injury [27]. This evidence concerns the gene IL6 and acute respiratory distress syndrome.